# Verastem Oncology

Source: https://onco.cc/companies/verastem/  
OnCo record `verastem` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RAS/MAPK-pathway company whose avutometinib + defactinib combination became the first approved treatment for KRAS-mutant low-grade serous ovarian cancer (May 2025).

## Summary

Verastem Oncology, based in Needham, Massachusetts, and listed as VSTM, is a RAS and MAPK pathway company whose combination of avutometinib and defactinib became the first approved treatment for KRAS-mutant low-grade serous ovarian cancer in May 2025. The AVMAPKI FAKZYNJA CO-PACK, pairing the RAF and MEK clamp avutometinib with the FAK inhibitor defactinib, received accelerated approval on 8 May 2025 on the RAMP 201 trial, and the company is also developing a KRAS G12D inhibitor, VS-7375, and combinations in pancreatic cancer with GenFleet. OnCo links it to ovarian and pancreatic cancer, to kinase and KRAS inhibitors, to KRAS as a target and the MAPK pathway, and to the RAMP 201 trial and the combination drug record. Whether the combination extends into pancreatic cancer is the open question. Avutometinib plus defactinib has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Needham, MA
- Type: biotech
- Website: https://www.verastem.com
- Ticker: VSTM

## Sources

- FDA approval: https://investor.verastem.com/news-releases/news-release-details/fda-approves-avmapkitm-fakzynjatm-combination-therapy-first-ever

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- drugs: [Avutometinib + defactinib](https://onco.cc/drugs/avutometinib-defactinib/), [VS-7375](https://onco.cc/drugs/vs-7375/)
- pathways: [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/)
- trials: [A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors](https://onco.cc/trials/nct07020221/), [A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer](https://onco.cc/trials/nct07659795/), [A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07659782/), [A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer](https://onco.cc/trials/nct07644559/), [A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer](https://onco.cc/trials/nct06072781/), [A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients](https://onco.cc/trials/nct06682572/), [Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients](https://onco.cc/trials/nct05074810/), [RAMP 201](https://onco.cc/trials/ramp-201/), [Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer](https://onco.cc/trials/nct05669482/)
- companies: [GenFleet Therapeutics](https://onco.cc/companies/genfleet/)

---
JSON: https://onco.cc/api/v1/entities/verastem.json